Press release
Zevra Reports First Quarter 2025 Financial Results and Corporate Update
Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"Q1 2025 net revenue of $20.4 million, driven by product net revenue of $17.2 million Completed sale of PRV for gross proceeds of $150 million, positioning balance sheet to drive the Company’s commercial launches and development programs Company to host conference call and webcast today, May 13, 2025, at 4:30 p.m. ET CELEBRATION, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended Mar. 31, 2025. “We are continuing Zevra's transformation into a patient-centric, commercial-stage rare disease therapeutics company,” said Neil F. McFarlane, Zevra’s President and Chief Executive Officer. “With our bolstered cash balance, we are well-positioned to support our strategic priorities, including establishing MIPLYFFA® as the cornerstone of treatment for NPC globally, maximizing our commercial opportunity with OLPRUVA®, and supporting our growth through our development pipeline.” Commercial Highlights All active patients in the U.S. Expanded Access Program (EAP) for arimoclomol, have been enrolled to receive MIPLYFFA. The EAP has since closed, including locking the database and deactivating study sites. MIPLYFFA: 13 new prescription enrollment forms during Q1 2025, marking 122 total through the end of the quarter. In line with expectations at this stage of launch, market access is 38% of covered lives. OLPRUVA: 5 new patient enrollment forms were received in Q1 2025, bringing the total from initial product availability in July 2023, and including Zevra's promotion of OLPRUVA since late January 2024, to 28. Market access has increased to 78% of covered lives. Pipeline and Innovation Highlights Filing of the MIPLYFFA MAA with the European Medicines Agency remains on track for the second half of 2025 as reinforced by recent conversations with European authorities. Enrolled 5 additional patients in the Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome, bringing the total number of enrolled patients to 32. The company out-licensed IP related to a pre-clinical prodrug that had been deprioritized. Zevra is entitled to receive a nominal upfront cash payment, potential future regulatory milestones, and...